



26-28 SETTEMBRE 2022

10° CONGRESSO NAZIONALE

**SIMPIOS**

**SIMPIOS**

Società Italiana Multidisciplinare per la Prevenzione  
delle Infezioni nelle Organizzazioni Sanitarie

# Chi è il chirurgo “champion”?

francesco cortese

U.O.C. di chirurgia d'urgenza / P.O. San Filippo Neri, Roma

Consulente Infettivologo ASLRoma1





26-28 SETTEMBRE 2022

10° CONGRESSO NAZIONALE

# SIMPIOS

# SIMPIOS

Società Italiana Multidisciplinare per la Prevenzione  
delle Infezioni nelle Organizzazioni Sanitarie





26-28 SETTEMBRE 2022

10° CONGRESSO NAZIONALE

**SIMPIOS**

**SIMPIOS**

Società Italiana Multidisciplinare per la Prevenzione delle Infezioni nelle Organizzazioni Sanitarie

Sartelli et al. *World Journal of Emergency Surgery* (2018) 13:37  
<https://doi.org/10.1186/s13017-018-0198-x>

World Journal of  
Emergency Surgery

COMMENTARY

Open Access

Knowledge, awareness, and attitude towards infection prevention and management among surgeons: identifying the surgeon champion



Virulence 4:2, 192–202; February 15, 2013; © 2013 Landes Bioscience

How to educate prescribers  
in antimicrobial stewardship practices

Céline Pulcini<sup>1,2</sup> and Inge C. Gyssens<sup>3,4,\*</sup>

<sup>1</sup>Service d'Infectiologie; CHU de Nice; Nice, France; <sup>2</sup>Faculté de Médecine; Université Nice-Sophia Antipolis; Nice, France; <sup>3</sup>Radboud University Nijmegen Medical Centre and Canisius Wilhelmina Hospital; Nijmegen, The Netherlands; <sup>4</sup>Hasselt University; Hasselt, Belgium





26-28 SETTEMBRE 2022

10° CONGRESSO NAZIONALE

# SIMPIOS


# SIMPIOS

Società Italiana Multidisciplinare per la Prevenzione delle Infezioni nelle Organizzazioni Sanitarie

## Surgeon Burnout: Defining, Identifying, and Addressing the New Reality

James C. Senturk, MD, PhD<sup>1</sup> Nelya Melnitchouk, MD, MSc, FACS<sup>1</sup>

<sup>1</sup>Department of Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts  
Address for correspondence: James C. Senturk, MD, PhD, Department of Surgery, Brigham and Women's Hospital, Harvard Medical School, 75 Francis Street, Boston, MA 02215 (e-mail: jsenturk@partners.org).  
Clin Colon Rectal Surg 2019;32:407-414.





26-28 SETTEMBRE 2022



10° CONGRESSO NAZIONALE

# SIMPIOS

# SIMPIOS

Società Italiana Multidisciplinare per la Prevenzione delle Infezioni nelle Organizzazioni Sanitarie

## Pharmacokinetics





26-28 SETTEMBRE 2022

10° CONGRESSO NAZIONALE

**SIMPIOS**

**SIMPIOS**

Società Italiana Multidisciplinare per la Prevenzione  
delle Infezioni nelle Organizzazioni Sanitarie



**Prevenzione e  
controllo delle ICA  
e degli MDRO:  
è ora di cambiare!**

**Dalla dissonanza cognitiva al tempio-*soft skill* ...**





26-28 SETTEMBRE 2022


10° CONGRESSO NAZIONALE

**SIMPIOS**

**SIMPIOS**

Società Italiana Multidisciplinare per la Prevenzione  
delle Infezioni nelle Organizzazioni Sanitarie

# Dissonanza cognitiva



A MAN WITH A CONVICTION is a hard man to change. Tell him you disagree and he turns away. Show him facts or figures and he questions your sources. Appeal to logic and he fails to see your point.

— Leon Festinger —

AZ QUOTES






26-28 SETTEMBRE 2022

10° CONGRESSO NAZIONALE

# SIMPIOS

# SIMPIOS

Società Italiana Multidisciplinare per la Prevenzione delle Infezioni nelle Organizzazioni Sanitarie





26-28 SETTEMBRE 2022

10° CONGRESSO NAZIONALE

# SIMPIOS

# SIMPIOS

Società Italiana Multidisciplinare per la Prevenzione delle Infezioni nelle Organizzazioni Sanitarie





26-28 SETTEMBRE 2022

10° CONGRESSO NAZIONALE

# SIMPIOS

MAJOR ARTICLE

Antibiotic Combinations with Redundant Antimicrobial Spectra: Clinical Epidemiology and Pilot Intervention of Computer-Assisted Surveillance

Robert C. Slovacek,<sup>1,2</sup> David N. Schwartz,<sup>1,3</sup> Gail S. Itokazu,<sup>1,4</sup> Mary F. Wisniewski,<sup>1</sup> Piotr Kieszowski,<sup>1</sup> and Robert A. Weinstein<sup>1,4</sup>

<sup>1</sup>John H. Stroger, Jr., Hospital of Cook County, <sup>2</sup>University of Illinois at Chicago College of Pharmacy, and <sup>3</sup>Trish Medical College, Chicago, Illinois

**Table 2. Most common redundant antibiotic combinations associated with intentional or unintentional physician prescribing errors.**

Antibiotic combination	No. (%) of times redundant regimen prescribed <sup>a</sup> (n = 77)
Piperacillin-tazobactam and cefazolin	6 (8)
Vancomycin and cefazolin	5 (7)
Clindamycin and cefazolin	5 (7)
Levofloxacin and erythromycin	5 (7)
Clindamycin and penicillin	4 (5)
Cefoxitin and metronidazole	4 (5)
Clindamycin and piperacillin-tazobactam	3 (4)
Ceftriaxone and amoxicillin-clavulanic acid	3 (4)
Piperacillin-tazobactam and ceftazidime	3 (4)

<sup>a</sup> Thirty-nine episodes of administration of redundant antibiotic combinations that occurred once or twice are not listed.

# SIMPIOS

Società Italiana Multidisciplinare per la Prevenzione delle Infezioni nelle Organizzazioni Sanitarie






26-28 SETTEMBRE 2022

10° CONGRESSO NAZIONALE

# SIMPIOS

# SIMPIOS

Società Italiana Multidisciplinare per la Prevenzione delle Infezioni nelle Organizzazioni Sanitarie





26-28 SETTEMBRE 2022

10° CONGRESSO NAZIONALE

# SIMPIOS

# SIMPIOS

Società Italiana Multidisciplinare per la Prevenzione delle Infezioni nelle Organizzazioni Sanitarie





26-28 SETTEMBRE 2022

10° CONGRESSO NAZIONALE

**SIMPIOS**

**SIMPIOS**

Società Italiana Multidisciplinare per la Prevenzione  
delle Infezioni nelle Organizzazioni Sanitarie

Ottica additiva ... *always learning.*





26-28 SETTEMBRE 2022

# 10° CONGRESSO NAZIONALE SIMPIOS

# SIMPIOS


Società Italiana Multidisciplinare per la Prevenzione delle Infezioni nelle Organizzazioni Sanitarie

ORIGINAL ARTICLE

INFECTIOUS DISEASES

**Close cooperation between infectious disease physicians and attending physicians can result in better management and outcome for patients with *Staphylococcus aureus* bacteraemia**

M. Nagao<sup>1,2</sup>, Y. Iinuma<sup>1,2</sup>, T. Saito<sup>4</sup>, Y. Matsumura<sup>1,2</sup>, M. Shirano<sup>1,2</sup>, A. Matsushima<sup>1,2</sup>, S. Takakura<sup>1,2</sup>, Y. Ito<sup>1,3</sup> and S. Ichiyama<sup>1,2</sup>  
1) Department of Infection Control and Prevention, Kyoto University Hospital, 2) Department of Clinical Laboratory Medicine, Kyoto University Graduate School of Medicine, 3) Department of Respiratory Medicine, Kyoto University Graduate School of Medicine, Kyoto and 4) Department of Clinical laboratory, Shiga Medical Center for Adults, Shiga, Japan





26-28 SETTEMBRE 2022

10° CONGRESSO NAZIONALE

**SIMPIOS**

**SIMPIOS**

Società Italiana Multidisciplinare per la Prevenzione delle Infezioni nelle Organizzazioni Sanitarie

### Telephone Consultation Cannot Replace Bedside Infectious Disease Consultation in the Management of *Staphylococcus aureus* Bacteremia

E. Forsblom,<sup>1</sup> E. Ruotsalainen,<sup>1</sup> J. Ollgren,<sup>2</sup> and A. Järvinen<sup>1</sup>

<sup>1</sup>Division of Infectious Diseases, Department of Medicine, Helsinki University Central Hospital, and <sup>2</sup>National Institute for Health and Welfare, Helsinki, Finland

	Died <sup>a</sup> (n = 24)	Survived (n = 81)	OR (95% CI)	P Value
Age >60 y	9 (38)	34 (42)	0.83 (.33–2.12)	.69
Underlying diseases <sup>b</sup>				
Healthy or nonfatal disease	10 (42)	60 (74)	0.25 (.09–.65)	.003
Ultimately or rapidly fatal disease	14 (58)	21 (26)	4.00 (1.55–10.3)	.003
IDS consultation <sup>b</sup>				
Bedside <sup>c</sup>	7 (29)	64 (79)	0.11 (.04–.31)	<.0001
Telephone <sup>c</sup>	11 (46)	12 (15)	4.87 (1.77–13.4)	.001
No IDS <sup>c</sup>	6 (25)	5 (6)	5.07 (1.39–18.5)	.008
Radiology				
Transthoracic echocardiography	18 (75)	71 (88)	0.42 (.14–1.32)	.13
Transesophageal echocardiography	2 (8)	17 (21)	0.34 (.07–1.60)	.16
Whole-body CT	10 (42)	54 (67)	0.36 (.14–.91)	.027
Leukocyte indium-111 scintigraphy	6 (25)	29 (36)	0.59 (.21–1.67)	.32
Deep infection focus	18 (75)	63 (78)	0.86 (.29–2.48)	.86
Defervescence within 7 d	8 (33)	45 (56)	0.51 (.18–1.49)	.22





26-28 SETTEMBRE 2022

# 10° CONGRESSO NAZIONALE SIMPIOS

# SIMPIOS

Società Italiana Multidisciplinare per la Prevenzione delle Infezioni nelle Organizzazioni Sanitarie

Open Forum Infectious Diseases

MAJOR ARTICLE



## Infectious Diseases Consultation Reduces 30-Day and 1-Year All-Cause Mortality for Multidrug-Resistant Organism Infections

Jessie P. Sambam, Margaret A. Olson, Dustin Stevelyn, Jennie H. News, Henry M. Babcock, and Maria H. Kallal<sup>1</sup>  
<sup>1</sup>Division of Infectious Diseases and <sup>2</sup>Division of Pulmonary and Critical Care Medicine, Washington University School of Medicine, St. Louis, Missouri

**Table 1. 30-Day and 1-Year Mortality and Readmission Rates by Drug-Resistant Pathogen Group and ID Consultation Status**

Index Hospitalization Drug-Resistant Pathogen	30-d Mortality, %	1-y Mortality, %	Hospital Discharge Survivors, %	30-d Readmission, %	1-y Readmission, %
<i>Staphylococcus aureus</i> (n = 1674)	284 (17.0)	633 (37.8)	1412 (84.3)	428 (30.3)	840 (59.5)
ID consultation (n = 832)	87 (10.5)	259 (31.1)	753 (90.5)	240 (31.9)	457 (60.7)
No ID consultation (n = 842)	197 (23.4)	374 (44.4)	659 (78.3)	188 (28.5)	383 (58.1)
<i>Enterococcus</i> spp. (n = 807)	235 (29.1)	479 (59.4)	561 (69.5)	225 (40.1)	384 (68.4)
ID consultation (n = 359)	90 (25.1)	194 (54.0)	251 (69.9)	98 (39.0)	168 (66.9)
No ID consultation (n = 448)	145 (32.4)	285 (63.6)	310 (69.2)	127 (41.0)	216 (69.7)
<i>Enterobacteriaceae</i> (n = 1168)	185 (15.8)	434 (37.2)	975 (83.5)	298 (30.6)	585 (60.0)
ID consultation (n = 375)	31 (8.3)	116 (30.9)	329 (87.7)	85 (25.8)	202 (61.4)
No ID consultation (n = 793)	154 (19.4)	318 (40.1)	646 (81.5)	213 (33.0)	383 (59.3)
<i>Acinetobacter</i> spp. (n = 96)	35 (36.5)	53 (55.2)	61 (63.5)	13 (21.3)	33 (54.1)
ID consultation (n = 54)	16 (29.6)	27 (50)	37 (68.5)	7 (18.9)	21 (56.8)
No ID consultation (n = 42)	19 (45.2)	26 (61.9)	24 (57.1)	6 (25.0)	12 (50.0)
<i>Pseudomonas aeruginosa</i> (n = 190)	36 (18.9)	82 (43.2)	145 (76.3)	49 (33.8)	92 (63.4)
ID consultation (n = 77)	13 (16.9)	36 (46.8)	59 (75.3)	23 (39.0)	41 (69.5)
No ID consultation (n = 113)	23 (20.4)	46 (40.7)	86 (76.1)	26 (30.2)	51 (59.3)
Polymicrobial (n = 279)	65 (23.3)	151 (54.1)	185 (66.3)	63 (34.1)	115 (62.2)
ID consultation (n = 146)	25 (17.1)	85 (58.2)	93 (63.7)	31 (33.3)	57 (61.3)
No ID consultation (n = 133)	40 (30.1)	66 (49.6)	92 (69.2)	32 (34.8)	58 (63.0)





26-28 SETTEMBRE 2022

10° CONGRESSO NAZIONALE

**SIMPIOS**

**SIMPIOS**

Società Italiana Multidisciplinare per la Prevenzione delle Infezioni nelle Organizzazioni Sanitarie

## Risk of Subsequent Sepsis Within 90 Days After a Hospital Stay by Type of Antibiotic Exposure

James Baggs, John A. Jernigan, Alison Laufer Halpin, Lauren Epstein, Kelly M. Hatfield, and L. Clifford McDonald

Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia

**Conclusions.** Our study identified an increased risk of sepsis within 90 days of discharge among patients with exposure to high-risk antibiotics or increased quantities of antibiotics during hospitalization. Given that a significant proportion of inpatient antimicrobial use may be unnecessary, this study builds on previous evidence suggesting that increased stewardship efforts in hospitals may not only prevent antimicrobial resistance, *Clostridium difficile* infection, and other adverse effects, but may also reduce unwanted outcomes potentially related to disruption of the microbiota, including sepsis.

516 ospedali / 14.120.553 casi





26-28 SETTEMBRE 2022

10° CONGRESSO NAZIONALE

**SIMPIOS**

**SIMPIOS**

Società Italiana Multidisciplinare per la Prevenzione  
delle Infezioni nelle Organizzazioni Sanitarie

cefalosporine III / IV generazione  
fluorchinoloni  
lincosamidi  
beta-lattammici CON inibitori  
vancomicina per os  
carbapenemici

cefalosporine I / II generazione  
macrolidi  
tetracicline  
metronidazolo  
aminoglicosidi  
vancomicina in vena





26-28 SETTEMBRE 2022

10° CONGRESSO NAZIONALE

# SIMPIOS

# SIMPIOS

Società Italiana Multidisciplinare per la Prevenzione delle Infezioni nelle Organizzazioni Sanitarie


DE GRUYTER

Diagnosis 2019; aop

David E. Newman-Toker\*, Adam C. Schaffer, C. Winnie Yu-Moe, Najlla Nassery, Ali S. Saber Tehrani, Gwendolyn D. Clemens, Zheyu Wang, Yuxin Zhu, Mehdi Fanai and Dana Siegal\*

## Serious misdiagnosis-related harms in malpractice claims: The “Big Three” – vascular events, infections, and cancers

“Big Three” breakdown of high-severity harms among diagnostic error claim cases GRICO 2006–2015 (n = 7379)





26-28 SETTEMBRE 2022

10° CONGRESSO NAZIONALE

**SIMPIOS**

**SIMPIOS**

Società Italiana Multidisciplinare per la Prevenzione delle Infezioni nelle Organizzazioni Sanitarie

Table 3. Clinical and Postmortem Causes of Death

		Clinical	Postmortem
Irreversible MODS	<i>n</i> (%)	134 (57)	121 (51.5)
Cardiovascular failure	<i>n</i> (%)	51 (21.7)	83 (35.3)
Intestinal ischemia	<i>n</i> (%)	14 (6)	5 (2.1)
Chronic peritonitis	<i>n</i> (%)	9 (3.8)	7 (3)
Pulmonary failure	<i>n</i> (%)	9 (3.8)	9 (3.8)
CNS failure	<i>n</i> (%)	8 (3.4)	3 (1.3)
Liver failure	<i>n</i> (%)	6 (2.6)	4 (1.7)
Uncontrolled hemorrhage	<i>n</i> (%)	4 (1.7)	3 (1.3)

MODS = multiple organ dysfunction syndrome; CNS = central nervous system.



26-28 SETTEMBRE 2022

10° CONGRESSO NAZIONALE

**SIMPIOS**

**SIMPIOS**

Società Italiana Multidisciplinare per la Prevenzione  
delle Infezioni nelle Organizzazioni Sanitarie

180 pazienti / 76% focolaio settico attivo

80 (34%) 1 focus

72 (30.6%) 2 foci

21 (8.9%) 3 foci

7 (3%)  $\geq$  4 foci

Torgersen C et al Macroscopic postmortem findings  
in 235 Surgical Intensive Care patients with sepsis  
Anesth Analg 2009 Jun;108(6): 1841-7





26-28 SETTEMBRE 2022

10° CONGRESSO NAZIONALE

# SIMPIOS

# SIMPIOS

Società Italiana Multidisciplinare per la Prevenzione delle Infezioni nelle Organizzazioni Sanitarie

De Waele and Sakr *Critical Care* (2019) 23:386  
<https://doi.org/10.1186/s13054-019-2675-3>

Critical Care

EDITORIAL

Open Access

## How I search for a sepsis source

Jan J. De Waele<sup>1\*</sup> and Yasser Sakr<sup>2</sup>



**Table 1** Recommended timing of source control procedures in patients with sepsis and septic shock

Emergent (within 1 h of diagnosis)	Urgent (within 6 h of diagnosis)	Delayed
Necrotizing skin and soft tissue infection debridement	Peritonitis with gastrointestinal leak	Infected pancreatic necrosis
CVC removal	Abdominal abscess	
Wound abscess drainage	Cholecystitis	
Peritonitis with abdominal compartment syndrome	Empyema drainage	





26-28 SETTEMBRE 2022

10° CONGRESSO NAZIONALE

**SIMPIOS**

**SIMPIOS**

Società Italiana Multidisciplinare per la Prevenzione  
delle Infezioni nelle Organizzazioni Sanitarie

*"One size fits all" strategy ...*





26-28 SETTEMBRE 2022

10° CONGRESSO NAZIONALE

**SIMPIOS**

**SIMPIOS**

Società Italiana Multidisciplinare per la Prevenzione  
delle Infezioni nelle Organizzazioni Sanitarie

SURGICAL INFECTIONS  
Volume 23, Number 3, 2022  
© Mary Ann Liebert, Inc.  
DOI: 10.1089/sur.2021.323

Open camera or QR reader and  
scan code to access this article  
and other resources online.



## Different Surgeon, Different Duration: Lack of Consensus on the Appropriate Duration of Antimicrobial Prophylaxis and Therapy in Surgical Practice

Patrick T. Delaplain,<sup>1</sup> Haytham M.A. Kaafarani,<sup>2</sup> L. Andrew O. Benedict,<sup>3</sup> Christopher A. Guidry,<sup>4</sup>  
Dennis Kim,<sup>5</sup> Michele M. Loo,<sup>6</sup> David Machado-Aranda,<sup>7</sup> Tina S. Mele,<sup>8</sup> April E. Mendoza,<sup>2</sup>  
Gareth Morris-Stiff,<sup>9</sup> Rishi Rattan,<sup>10</sup> Jeffrey S. Upperman,<sup>11</sup> Philip S. Barie,<sup>12</sup> and Sebastian D. Schubl<sup>1</sup>;  
Scientific Studies Committee of the Surgical Infection Society\*





26-28 SETTEMBRE 2022

10° CONGRESSO NAZIONALE

# SIMPIOS

# SIMPIOS


Società Italiana Multidisciplinare per la Prevenzione delle Infezioni nelle Organizzazioni Sanitarie

## Annals of Internal Medicine

### Excess Antibiotic Treatment Duration Hospitalized With Pneumonia

#### A Multihospital Cohort Study

Valerie M. Vaughn, MD, MSc; Scott A. Flanders, MD; Ashley Snyder Anurag N. Malani, MD; Elizabeth McLaughlin, MS, RN; Sarah Bloer Scott Kaatz, DO; Danielle Osterholzer, MD; Rama Thyagarajan, MD and Tejal N. Gandhi, MD



t's in a Name?

lege of Pharmacy, Missouri





26-28 SETTEMBRE 2022

10° CONGRESSO NAZIONALE

**SIMPIOS**

**SIMPIOS**

Società Italiana Multidisciplinare per la Prevenzione  
delle Infezioni nelle Organizzazioni Sanitarie

## Percutaneously drained intra-abdominal infections do not require longer duration of antimicrobial therapy

**Rishi Rattan, MD, Casey J. Allen, MD, Robert G. Sawyer, MD, Reza Askari, MD, Kaysie L. Banton, MD,  
Raul Coimbra, MD, PhD, Charles H. Cook, MD, Therese M. Duane, MD, Patrick J. O'Neill, MD, PhD,  
Ori D. Rotstein, MD, and Nicholas Namias, MD, Miami, Florida**

...





26-28 SETTEMBRE 2022

10° CONGRESSO NAZIONALE

**SIMPIOS**

**SIMPIOS**

Società Italiana Multidisciplinare per la Prevenzione  
delle Infezioni nelle Organizzazioni Sanitarie

## Postoperative Antimicrobial Prophylaxis Duration With Drain Use

19. In prosthetic joint arthroplasty, recommendation 1E applies: in clean and clean-contaminated procedures, do not administer additional antimicrobial prophylaxis doses after the surgical incision is closed in the operating room, even in the presence of a drain. (Cat-

...





26-28 SETTEMBRE 2022

10° CONGRESSO NAZIONALE

# SIMPIOS



Società Italiana Multidisciplinare per la Prevenzione delle Infezioni nelle Organizzazioni Sanitarie

UOC MICROBIOLOGIA E VIROLOGIA

## 'ANTIMICROBIAL STEWARDSHIP: TABELLE DI SENSIBILITÀ' AGLI ANTIBIOTICI (2017)

microorganismi identificati nel 2017

GRAM POSITIVI		Percentuale di microrganismi SENSIBILI (criteri EUCAST)																
Microorganismi implicati nei principali tipi di infezione batterica, nella ASL Roma 1		Ac.fusidic	Ampicillina	Clindamic	Ceftriaxone	Cefuroxime	Cotrimox	Daptomic	Eritromic	Gentamic	Levofloxa	Linezolid	Oxacillina	Rifampicina	Telaprevir	Tetracicli	Tigecicl	Vanomic
1	Staphylococcus aureus (n.348)	95	nd	57	nd	nd	96	98	50	92	43	100	43	89	100	93	100	100
2	Enterococcus faecalis (n.185)	nd	99	0	nd	0	0	nd	0	57 (*)	50	100	nd	nd	98	nd	100	98
3	Staphyloc. epidermidis (n.116)	66	nd	66	nd	nd	78	97	25	43	43	99	31	68	79	48	100	98
4	Enterococcus faecium (n.34)	nd	23	nd	nd	0	nd	nd	0	39 (*)	25	100	nd	nd	76	nd	100	73
5	Staphyloc. haemolyticus (n.26)	56	nd	64	nd	nd	52	100	8	19	23	100	11	75	100	20	100	100
6	Streptococcus pneumoniae (n.11)	nd	82	70	91	82	73	nd	54	nd	91	100	nd	nd	nd	45	nd	100

GRAM NEGATIVI		Percentuale di microrganismi SENSIBILI (criteri EUCAST)																		
Microorganismi implicati nei principali tipi di infezione batterica, nella ASL Roma 1		Amikacina	Amox.clav	Cefepime	Cefotaxim	Ceftazidim	Ciprofloxa	Cloramfen	Colistina	Cotrimoxa	Ertapenam	Fosfomicil	Gentamicil	Imipenem	Meropenem	Meropenem	Meropenem	Metronidol	Pip.t.azob	Tigeciclin
1	Escherichia coli (n.758)	86	69	77	73	74	57	nd	97	78	100	96	84	100	100	nd	nd	86	100	
2	Klebsiella spp. (n.263)	82	61	65	65	64	58	nd	87	61	88	75	74	88	82	nd	nd	86	100	
3	Pseudomonas aeruginosa (n.167)	83	0	82	0	79	66	nd	92	0	0	nd	88	88	78	nd	nd	86	0	
4	Proteus spp. (n.151)	72	66	67	54	52	37	nd	0	37	99	53	58	nd	99	nd	nd	88	0	
5	Acinetobacter spp. (n.69)	nd	0	nd	0	14	10	nd	88	13	0	nd	16	12	12	nd	nd	0	nd	
6	Enterobacter spp. (n.66)	97	2	85	66	65	89	nd	87	90	97	55	98	95	97	nd	nd	71	100	
7	Serratia (n.23)	77	0	100	100	100	83	nd	0	100	100	95	100	100	100	nd	nd	100	100	
8	Bacteroides spp. (n.26)	nd	68	nd	nd	nd	nd	100	nd	nd	nd	nd	nd	96	nd	92	84	nd	nd	

MICETI (lieviti)		% SENSIBILI (criteri CLSI)					
Microorganismi implicati nei principali tipi di infezione fungina, nella ASL Roma 1		Amfoteric	Anidulafur	Caspofung	Fluconazol	Posaconaz	Voriconaz
1	Candida albicans (n.17)	100	nd	100	100	nd	100
2	Candida, altre specie (n.10)	100	nd	98	98	nd	100

**ANTIBIOGRAMMA CUMULATIVO**

NOTE:  
 - nd = antibiotico non testato, o dato non valido  
 - (\*) Gentamicina alta concentrazione  
 - per la Candida sono stati valutati: gli isolati da sangue, liquor e pus

**BASATO SUI DATI 2017**



Basato sugli esecutori microbiologici della UOOC di degenza dei presidi S.Filippo Neri, S. Spirito in Saeta, O.Rainico, S. Andrea, Nuovo Regina Margherita e della CUC Salaria Infermeria

Dati relativi agli isolati clinici unici di maggiore frequenza del 2017



Grazie, Marcello ...



26-28 SETTEMBRE 2022

10° CONGRESSO NAZIONALE

**SIMPIOS**

**SIMPIOS**

Società Italiana Multidisciplinare per la Prevenzione delle Infezioni nelle Organizzazioni Sanitarie

## Source control in the management of severe sepsis and septic shock: An evidence-based review

John C. Marshall, MD; Ronald V. Maier, MD, FACS; Maria Jimenez, MD; E. Patchen Dellinger, MD

**Table 2. Ease of removal of colonized devices**

Increasing risk associated  
with removal



Urinary catheter  
Intravascular catheter  
Endotracheal tube  
Peritoneal dialysis catheter  
Prosthetic joint; orthopedic hardware  
Vascular graft  
Prosthetic heart valve  
Left ventricular assist device



26-28 SETTEMBRE 2022

10° CONGRESSO NAZIONALE

**SIMPIOS**

**SIMPIOS**

Società Italiana Multidisciplinare per la Prevenzione delle Infezioni nelle Organizzazioni Sanitarie

Clinical Infectious Diseases

**IDSA FEATURES**



## Clinical Practice Guideline for the Management of Asymptomatic Bacteriuria: 2019 Update by the Infectious Diseases Society of America<sup>a</sup>

Lindsay E. Nicolle,<sup>1</sup> Kalpana Gupta,<sup>2</sup> Suzanne F. Bradley,<sup>3</sup> Richard Colgan,<sup>4</sup> Gregory P. DeMuri,<sup>5</sup> Dimitri Drekonja,<sup>6</sup> Linda O. Eckert,<sup>7</sup> Suzanne E. Geerlings,<sup>8</sup> Béla Köves,<sup>9</sup> Thomas M. Hooton,<sup>10</sup> Manisha Juthani-Melita,<sup>11</sup> Shandra L. Knight,<sup>12</sup> Sanjay Saint,<sup>13</sup> Anthony J. Schaeffer,<sup>14</sup> Barbara Trautner,<sup>15</sup> Bjorn Wullt,<sup>16</sup> and Reed Siemieniuk<sup>17</sup>



Journal of  
**Clinical Microbiology**<sup>®</sup>

MINIREVIEW



## Targeting Asymptomatic Bacteriuria in Antimicrobial Stewardship: the Role of the Microbiology Laboratory

Zanthia Wiley,<sup>a</sup> Jesse T. Jacob,<sup>b</sup> Eileen M. Burd<sup>c</sup>





26-28 SETTEMBRE 2022

10° CONGRESSO NAZIONALE

**SIMPIOS**

**SIMPIOS**

Società Italiana Multidisciplinare per la Prevenzione delle Infezioni nelle Organizzazioni Sanitarie

**TABLE 1** Microbiologic definition of asymptomatic<sup>a</sup> bacteriuria<sup>b</sup>

**Criteria for ASB diagnosis**

Two consecutive voided urine specimens (preferably within 2 wk) with the same bacterial species isolated in quantitative count of  $>10^5$  CFU/ml in women, including pregnant women (1, 2)

A single voided urine specimen with one bacterial species isolated in a quantitative count of  $>10^5$  CFU/ml in men (1, 2)

A single catheterized urine specimen with one or more bacterial species isolated in a quantitative count of  $>10^5$  CFU/ml in either women or men (1) or  $\geq 10^2$  CFU/ml of a single bacterial species from a single catheterized urine specimen (2)

Any urine specimen with  $>10^4$  CFU/ml of group B *Streptococcus* is significant for ASB in a pregnant woman (3)

<sup>a</sup>No signs or symptoms referable to the urinary tract, e.g., typical urinary tract symptoms include urinary frequency, urinary urgency, lower abdominal pain, pelvic pain, and/or flank pain.

<sup>b</sup>Presence of more than one bacterial type indicates contamination with organisms normally found on the skin. The presence of yeast in the urine of asymptomatic patients is almost always the result of external genital tract colonization, and there are no consistent diagnostic criteria to define significant infection (7).

AMERICAN SOCIETY FOR MICROBIOLOGY Journal of Clinical Microbiology®



Targeting Asymptomatic Bacteriuria in Antimicrobial Stewardship: the Role of the Microbiology Laboratory

Zanitha Wiley,\* Jesse T. Jacob,\* Eileen M. Burd\*





26-28 SETTEMBRE 2022

# 10° CONGRESSO NAZIONALE SIMPIOS

# SIMPIOS

Società Italiana Multidisciplinare per la Prevenzione  
delle Infezioni nelle Organizzazioni Sanitarie

## XIV. What Is the Treatment for Urinary Tract Infections Due to *Candida* Species?

### *What Is the Treatment for Asymptomatic Candiduria?*

#### *Recommendations*

97. Elimination of predisposing factors, such as indwelling bladder catheters, is recommended whenever feasible (*strong recommendation; low-quality evidence*).
98. Treatment with antifungal agents is NOT recommended unless the patient belongs to a group at high risk for dissemination; high-risk patients include neutropenic patients, very low-birth-weight infants (<1500 g), and patients who will undergo urologic manipulation (*strong recommendation; low-quality evidence*).

Clinical Practice Guideline for the Management of  
Candidiasis: 2016 Update by the Infectious Diseases  
Society of America

Peter G. Pappas,<sup>1</sup> Carol A. Kauffman,<sup>2</sup> David R. Andes,<sup>3</sup> Cornelius J. Clancy,<sup>4</sup> Kieren A. Marr,<sup>5</sup> Luis Ostrosky-Zeichner,<sup>6</sup> Annette C. Reboli,<sup>7</sup> Mindy G. Schuster,<sup>8</sup>  
Jose A. Vazquez,<sup>9</sup> Thomas J. Walsh,<sup>10</sup> Theoklis E. Zaoutis,<sup>11</sup> and Jack D. Sobel<sup>12</sup>

The presence of candiduria is the usual trigger for a physician to consider whether a patient has a urinary tract infection due to *Candida* species. The patients at most risk for candiduria are those who are elderly, female, diabetic, have indwelling urinary devices, are taking antibiotics, and have had prior surgical procedures [470–475]. In the asymptomatic patient, candiduria almost always represents colonization, and elimination of underlying risk factors, such as indwelling catheters, is often adequate to eradicate candiduria [471].

Multiple studies have noted that candiduria does not commonly lead to candidemia [471, 472, 476–480]. Several of these studies have shown that candiduria is a marker for greater mortality, but death is not related to *Candida* infection and treatment for *Candida* infection does not change mortality rates [476, 480, 481]. A prospective study in renal transplant recipients found that although mortality was higher in patients who had candiduria, treatment did not improve outcomes, suggesting again that candiduria is a marker for severity of underlying illness [482].





26-28 SETTEMBRE 2022

# 10° CONGRESSO NAZIONALE SIMPIOS

# SIMPIOS

Società Italiana Multidisciplinare per la Prevenzione delle Infezioni nelle Organizzazioni Sanitarie

## *Clostridioides difficile*

Table 1. *Clostridium difficile* Infection Control Plan\*

<ul style="list-style-type: none"> <li>Education           <ul style="list-style-type: none"> <li>Yearly education for physicians, nurses, allied health professionals re: infection control</li> </ul> </li> <li>Environmental Services           <ul style="list-style-type: none"> <li>Enhance daily room cleaning ✓               <ul style="list-style-type: none"> <li>Determine who is responsible for cleaning specific items in rooms ✓</li> <li>Need more housekeeper full-time equivalents (FTEs) to adequately clean rooms ✓</li> <li>Hypochlorite-based cleaning agent for isolation rooms ✓</li> <li>Environmental Services monitors compliance and reports back to patient care unit, infection control, and hospital administration ✓</li> </ul> </li> <li>Enhance discharge room cleaning of all patient rooms               <ul style="list-style-type: none"> <li>Assess need for more housekeeper FTEs to adequately clean rooms ✓</li> <li>Use hypochlorite-based cleaning agent used for isolation room discharge cleaning ✓</li> <li>Environmental Services monitors compliance and sends reports to patient care unit, infection control, and hospital administration ✓</li> </ul> </li> </ul> </li> <li>Single-use Devices for Isolation Rooms           <ul style="list-style-type: none"> <li>Blood pressure cuff, thermometer, and stethoscope in every isolation room</li> <li>Nursing staff monitors compliance and sends report to infection control and hospital administration</li> </ul> </li> <li>Review policies re: cleaning portable equipment ✓           <ul style="list-style-type: none"> <li>Determine who is responsible for maintaining cleaning and cleaning supplies ✓</li> </ul> </li> <li>Personal protective equipment for isolation rooms readily available (gowns, gloves, masks as needed)           <ul style="list-style-type: none"> <li>Need to be easily accessible and readily available ✓</li> <li>Need appropriate sizes ✓</li> <li>Need easily accessible and frequently emptied hamper bins ✓</li> <li>Monitor compliance and report back to patient care unit, infection control, and hospital administration</li> </ul> </li> <li>Robust antibiotic stewardship program for all hospital patient care units           <ul style="list-style-type: none"> <li>Regularly scheduled prospective audits of antibiotic use with direct interaction and feedback to the prescriber</li> <li>Formulary restriction and preauthorization requirements</li> <li>Education of prescribers</li> <li>Use evidence-based practice guidelines and incorporate into computerized provider order entry system based on national guidelines, local microbiology, and hospital antimicrobial resistance patterns</li> <li>Assist in streamlining, or de-escalating empiric antibiotic therapy based on culture results, eliminating redundant combination therapy (done in ICUs)</li> <li>Optimize antimicrobial dosing based on individual patient characteristics, causative organism, site of infection, and pharmacokinetic and pharmacodynamic characteristics of the prescribed drug (done in ICUs)</li> <li>Assist in intravenous to oral conversion of antibiotics by developing clinical criteria and guidelines promoting conversion to use of oral agents (done in ICUs)</li> <li>Audit antibiotic class and specific antibiotic use over time and report data to chief medical officer</li> <li>Assist in narrow-spectrum antibiotic use ✓ (done for trauma surgery patients)</li> <li>Monitor process and outcome data and report to infection control, quality assurance, and hospital administration ✓</li> </ul> </li> <li>Develop a tool to determine patients at high risk for <i>C. difficile</i> and automate orders for isolation precautions and <i>C. difficile</i> testing along with automated notification of physician and nursing team caring for individual patients           <ul style="list-style-type: none"> <li>Empower nurses to initiate contact precautions and order <i>C. difficile</i> toxin assay on patients with diarrhea without a physician's order as part of a nursing protocol ✓</li> </ul> </li> <li>Improve sensitivity of <i>C. difficile</i> testing           <ul style="list-style-type: none"> <li>Change <i>C. difficile</i> testing method to a more sensitive method ✓</li> <li>Increase frequency of testing done by microbiology laboratory ✓</li> </ul> </li> <li>Develop a medical/surgical guideline for <i>C. difficile</i> management ✓           <ul style="list-style-type: none"> <li>Incorporate into computerized provider order entry system</li> <li>Monitor compliance and outcome data and report to hospital administration</li> </ul> </li> <li>Develop a medical/surgical rapid response team for severe <i>C. difficile</i> management           <ul style="list-style-type: none"> <li>Monitor outcome data and report to hospital administration</li> </ul> </li> <li>Consider expanding isolation precautions for patients with <i>C. difficile</i> infection for the duration of hospitalization</li> </ul>	<ul style="list-style-type: none"> <li>Robust antibiotic stewardship program for all hospital patient care units           <ul style="list-style-type: none"> <li>Regularly scheduled prospective audits of antibiotic use with direct interaction and feedback to the prescriber</li> <li>Formulary restriction and preauthorization requirements</li> <li>Education of prescribers</li> <li>Use evidence-based practice guidelines and incorporate into computerized provider order entry system based on national guidelines, local microbiology, and hospital antimicrobial resistance patterns</li> <li>Assist in streamlining, or de-escalating empiric antibiotic therapy based on culture results, eliminating redundant combination therapy (done in ICUs)</li> <li>Optimize antimicrobial dosing based on individual patient characteristics, causative organism, site of infection, and pharmacokinetic and pharmacodynamic characteristics of the prescribed drug (done in ICUs)</li> <li>Assist in intravenous to oral conversion of antibiotics by developing clinical criteria and guidelines promoting conversion to use of oral agents (done in ICUs)</li> <li>Audit antibiotic class and specific antibiotic use over time and report data to chief medical officer</li> <li>Assist in narrow-spectrum antibiotic use ✓ (done for trauma surgery patients)</li> <li>Monitor process and outcome data and report to infection control, quality assurance, and hospital administration ✓</li> </ul> </li> </ul>
---	---





26-28 SETTEMBRE 2022

10° CONGRESSO NAZIONALE

# SIMPIOS

# SIMPIOS

Società Italiana Multidisciplinare per la Prevenzione delle Infezioni nelle Organizzazioni Sanitarie

ACS Infectious Diseases

[pubs.acs.org/journal/aidtbc](https://pubs.acs.org/journal/aidtbc)



Review

## Exotoxin-Targeted Drug Modalities as Antibiotic Alternatives

Moona Sakari, Arttu Laisi, and Arto T. Pulliainen\*

Cite This: *ACS Infect. Dis.* 2022, 8, 433–456

[Read Online](#)


### Antibiotics

#### Bacteriostatic



bacteria do not multiply  
exotoxins active

#### Bactericidal



bacteria die  
exotoxins active

### Exotoxin-targeted drugs



bacteria multiply  
exotoxins inactive



SISTEMA SANITARIO REGIONALE

ASL  
ROMA 1





26-28 SETTEMBRE 2022

10° CONGRESSO NAZIONALE

**SIMPIOS**

**SIMPIOS**

Società Italiana Multidisciplinare per la Prevenzione  
delle Infezioni nelle Organizzazioni Sanitarie

Sartelli et al. *World Journal of Emergency Surgery* (2020) 15:28  
<https://doi.org/10.1186/s13017-020-00308-1>

World Journal of  
Emergency Surgery

**COMMENTARY**

**Open Access**

Hey surgeons! It is time to lead and be a  
champion in preventing and managing  
surgical infections!

